ARTICLE | Company News
BioChem, Biovector deal
February 22, 2000 8:00 AM UTC
The companies will develop a nasal vaccine against Streptococcus pneumoniae that combines BCHE’s protein antigen with Biovector’s Light Biovector Systems drug delivery technology. The vaccine is the s...